$4 billion increase in Alzheimer’s funding needed to prevent ‘catastrophe,’ coalition with provider...
By
Kimberly Bonvissuto
Jul 11, 2023
Funding the national response to Alzheimer’s and related dementias is a “national priority, economic and budgetary necessity, health and moral imperative,” according to a coalition of 360 organizations...
FDA gives full approval to Alzheimer’s disease drug Leqembi
Jul 06, 2023
Although Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds.
$14.6 million study, a first, aims to combat dementia in Native, Pacific Islander communities
By
Kimberly Bonvissuto
May 24, 2023
A first-ever study will adapt Alzheimer’s tests for Indigenous communities to expand treatment and research options for dementia in those populations.
FDA approves first drug meant to ease Alzheimer’s disease-llnked agitation
May 11, 2023
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo.
$215,000 disability discrimination complaint could have ‘broader ramifications’ on resident contracts,...
By
Kimberly Bonvissuto
Apr 12, 2023
A Pennsylvania continuing care retirement community agreed to a $215,000 Fair Housing Act settlement over allegations of disability discrimination, but the senior living owners and operators said that...
US sets up $300 million database for Alzheimer’s disease research
Apr 05, 2023
In creating the database, the goal is to provide something that can “improve applicability and generalizability of findings.”
AI model using health records predicts Alzheimer’s disease up to 5 years before diagnosis
By
Kimberly Bonvissuto
Mar 01, 2023
A team of researchers designed an artificial intelligence system that can predict which individuals will develop Alzheimer’s disease up to five years before a diagnosis.
Bipartisan group pushes CMS to expand coverage for Alzheimer’s treatments
By
Kimberly Bonvissuto
Feb 21, 2023
Access to federally approved monoclonal antibody and other disease-modifying therapies for Alzheimer’s disease will be “extremely limited” unless the Centers for Medicare & Medicaid Services reconsiders...
Focus on briefs: Dementia
Feb 01, 2023
Alzheimer’s blood test, Aducanumab approval issues, Medicare coverage of brain scans that diagnose dementia, Some at higher risk for Alzheimer’s
Increasing workforce, providing training top Alzheimer’s task force goals
By
Kimberly Bonvissuto
Jan 31, 2023
Increasing the workforce and providing dementia competency training are among the recommendations from a Missouri task force on Alzheimer’s care.